Overview

A Study Of PF-04620110 As A Modified-Release Formulation In Healthy Overweight Or Obese Subjects

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, of multiple oral doses of PF-04620110 as a modified-release formulation.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer